The global pandemic of SARS-CoV-2 infection continues in the majority of the world’s 195 countries, checked only by non-pharmacetical interventions and restriction of human movement, and with catastrophic economic and social cost. The cost of human life, and the substantial morbidity in persons recovering from COVID-19, associated with attaining herd protection (estimated at >60% of the population with immunity) through natural infection are unimaginable. Mass vaccination with effective and safe vaccines is therefore undoubtedly the best option for all countries, including South Africa (SA), to minimise the health, economic and social tragedies of this pandemic.

A vaccine is a biological product that can safely induce an immune response that confers protection against infection and/or disease on further exposure to a pathogen. Numerous vaccines are in widespread use, and arguably vaccines as a group are the biggest single public health success, with an estimated 2 - 3 million lives saved each year by current immunisation programmes. There are excellent reviews of basic concepts in vaccinology as well as an updated vaccine tracker detailing the pipeline and phase I - III clinical trial details of approved and late-phase COVID-19 vaccines (https://vacc.shinyapps.io/ncoV_vaccine_landscape/); there are also now peer-reviewed publications of safety data for several of the candidate COVID-19 vaccines likely to be rolled out in SA, including the AstraZeneca-Oxford ChAdOx vaccine and Johnson & Johnson Ad26 vaccines.

The imminent approval and arrival of COVID-19 vaccines in SA has led to considerable focus on safe and rapid roll-out, and to individuals considering their own comorbidities and risk-benefits in receiving a specific approved vaccine. COVID-19 vaccines are the focus of heightened media coverage that has highlighted both the many vaccine candidates and the promise of vaccines, but also the shortened timeline of vaccine trials and approvals, as well as the recent series of anaphylaxis cases associated with the two approved mRNA COVID-19 vaccines. Patients with allergic and other immune-based diseases are subgroups especially concerned about vaccine safety and efficacy. This practice guideline offers broad recommendations for COVID-19 vaccination in various subgroups of allergic and immune-based disease, highlighting risk/benefit evaluation, and where and how routine vaccination should be altered.

Vaccine side-effects
All medications, vaccines included, can have side-effects. The majority of vaccine side-effects are mild, and by-products of the early innate immune response. Common side-effects include injection site pain, redness and swelling, and systemic symptoms such as fever, headache and malaise; these occur in the first 1 - 2 days following vaccination. Importantly for the population of patients with immunosuppression or immunodeficiencies, none of the current late-phase or approved candidate COVID-19 vaccines are live vaccines, as live vaccines such as the live intranasal influenza vaccine are contraindicated in patients with significant immunodeficiency. Serious side-effects from vaccines are rare and include allergy reactions and blood dyscrasias. Many people are alarmed by the identification of uncommon side-effects to vaccines or medications after approval by regulatory bodies in the post-marketing surveillance period. However, this is to be expected. Regulatory approvals for all vaccines, irrespective of the timeline of development (1 year or 10 years), are given with safety studies completed in 3 000 to tens of thousands of individuals. Rare side-effects may therefore not necessarily have been identified. Vaccine development is tightly controlled, and robust post-marketing surveillance systems are in place in SA and other countries to pick these side-effects up if they do occur. The SA National Department of Health will soon roll out an electronic reporting system for adverse events following immunisation (AEFI), allowing for national robust reporting of AEFI to occur.
Table 1. recommends COVID-19 (non-live) vaccine management in various allergy or immune-based disease groups (adults ≥18 years old)

<table>
<thead>
<tr>
<th>Allergy or immune-based disease history</th>
<th>VACCINE ACTION TO TAKE:</th>
<th>VACCINE ACTION TO TAKE:</th>
<th>VACCINE ACTION TO TAKE:</th>
<th>VACCINE ACTION TO TAKE:</th>
</tr>
</thead>
<tbody>
<tr>
<td>History of environmental allergies, allergies to food, pets, insect venom, latex or oral medications, or other allergies not related to vaccines or injectable therapy OR Family history of anaphylaxis OR Any anaphylaxis not related to a vaccine or injectable</td>
<td>Vaccinate</td>
<td>Allergy assessment*</td>
<td>DO NOT vaccinate</td>
<td>Vaccinate if stable disease</td>
</tr>
<tr>
<td>History of severe allergic reaction to a non-COVID-19 vaccine</td>
<td>Vaccinate in hospital setting</td>
<td>Allergy specialist assessment*</td>
<td>Risk assessment if hospitalised or unstable* – consider deferred vaccination</td>
<td>15 minutes’ observation</td>
</tr>
<tr>
<td>History of severe allergic reaction to 1st dose of COVID-19 vaccine</td>
<td>30 minutes’ observation</td>
<td>30 minutes’ observation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Comorbid autoimmune condition or immunodeficiency (including patients on antibody replacement therapies) and HIV</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current immunosuppressive medication</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Facilities to be available at site of vaccination

<table>
<thead>
<tr>
<th>Medications</th>
<th>Equipment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epinephrine prefilled syringe or autoinjector</td>
<td>Monitoring – blood pressure cuff</td>
</tr>
<tr>
<td>Antihistamine promethazine</td>
<td>Pulse oximeter</td>
</tr>
<tr>
<td>Oxygen</td>
<td>Intubation kit and ventilation bag</td>
</tr>
<tr>
<td>Bronchodilators, e.g. salbutamol with spacer</td>
<td>Anaphylaxis management algorithm, including details of tryptase sampling in possible cases of anaphylaxis</td>
</tr>
<tr>
<td>Intravenous fluids</td>
<td></td>
</tr>
</tbody>
</table>

*Risk assessment should focus on the previous vaccine-related anaphylaxis and identification of the offending vaccine component, most commonly an excipient. Any possibility of a previous reaction to polysorbate 80 (a component in the AstraZeneca/Oxford COVID-19 vaccine) or polyethylene glycol (PEG) (a component in the Pfizer BioNTech vaccine) should warrant an allergy specialist review, which might include skin testing and low-dose vaccine challenge under supervision. Similarly, if an anaphylactic reaction to the 1st dose of COVID-19 vaccine occurs, patients should undergo full allergy assessment including testing for PEG and polysorbate sensitivity.

†Risk assessment should consider increased risk from COVID-19 disease, estimated efficacy of vaccination in unstable disease, e.g. current hospitalisation or newly diagnosed HIV with advanced immunosuppression. Consider deferring vaccination until disease has stabilised.

Anaphylaxis is a serious multisystem allergic reaction with a rapid onset; it can lead to death by asphyxiation, cardiovascular collapse and other complications. Fortunately, if promptly treated with intramuscular adrenaline, the majority of cases are quickly aborted, and studies show that the 1st dose of a mRNA COVID-19 vaccine was associated with an estimated 400 000 doses. Hence, the prevailing understanding is that anaphylaxis is a rare event following vaccination, at a rate of one case per 100 000 doses compared with an airplane crash, the risk of death is more than a 100-fold higher from a long-distance in a motor vehicle; statistically, the people fear flying, yet have no problem driving.
being aware of the utilitarian societal benefit of wide-scale vaccine uptake for herd protection.

The age-standardised risk of COVID-19 death in SA was reported at around 1 in 100 000 population; however, this risk increases substantially with each decade, and with risk factors for severity including obesity, diabetes, hypertension and chronic organ diseases. There have been conflicting data on whether asthma, autoimmune diseases and immunodeficiency states, e.g. HIV, having had a transplant, immunosuppressive therapies or primary immunodeficiencies, significantly increase risk in addition to age and the aforementioned risk factors, but the majority of emerging data mostly indicate a risk of increased severity associated with these diseases. Data are still lacking for many subgroups of uncommon immune-based diseases. For the majority of individuals with allergic and immune-based disease comorbidities, the risk of severe COVID-19-related disease will outweigh safety concerns of vaccination.

Detailed efficacy data for a specific COVID-19 vaccine in the majority of immune-based disease subgroups, including HIV, will be unavailable at the time of emergency-use authorisation and roll-out, because groups with severe unstable disease or known immunosuppression are mostly excluded from the initial large phase III trials (see https://clinicaltrials.gov/ct2/show/NCT04444674 for example protocol from the ChAdOx1 nCoV-19 trial). Fortunately, some stable HIV patients on antiretrovirals with suppressed viral loads have been included in clinical trials of most vaccines, and efficacy data will emerge in the coming months. The fact that there are no live COVID-19 vaccine candidates in the pipeline means that there will not be a contraindication to use in patients with secondary or primary immunodeficiency states or those receiving immunosuppressive therapies; however, these patients will need to be informed that use will be off-label and the efficacy of vaccination is unknown. It is hoped that the collection of large-scale roll-out data will provide this information in time, but extra counselling should be provided to these off-label patient groups to encourage ongoing rigorous use of non-pharmaceutical interventions to reduce the likelihood of infection.

Table 1 summarises pragmatic COVID-19 vaccine recommendations for different subgroups of patients with allergic or immune-based disease.

**Known allergic diseases**

Atopic diseases, including allergic rhinitis, asthma, atopic dermatitis and food or drug allergy, affect up to 30% of the SA population. Although vaccine- or drug-induced anaphylaxis is more common in atopic individuals, the risk is very small, and importantly, reactions are allergen-specific, meaning that unless the offending agent is a cross-reacting substance such as an excipient, that may be found in more than one vaccine or drug, even prior drug- or vaccine-induced anaphylaxis may not be an absolute contraindication to receiving a COVID-19 vaccine. Two important practice points should improve safety: (i) patients with prior anaphylaxis or severe allergic disease should be observed for 30 rather than 15 minutes after vaccination, as the majority of drug- or vaccine-induced anaphylaxis occurs within the first 30 minutes following the dose; and (ii) individuals with prior vaccine-associated anaphylaxis should have an allergy assessment and review by a specialist to ensure safety, and particularly the absence of sensitivity to excipients, e.g. polysorbate 80 or PEG in COVID-19 vaccines. A detailed review of allergy specialist assessment in the context of suspected reactions to PEG, polysorbate or the two recently approved mRNA COVID-19 vaccines is available for reference. It is recommended that vaccination should be done in facilities fully equipped and with experienced staff to manage allergic reactions should they arise.

**Known autoimmune disease**

Autoimmune or inflammatory disease as a group is common, and severe disease requires immunosuppression, including small-molecule therapies and biologicals. Vaccines stimulate an immune response and may contain adjuvants, raising mostly theoretical concerns around exacerbating inflammatory disease. To date, no studies have substantiated these with a robust evidence base. Furthermore, immune dysregulation and its treatment can often result in increased susceptibility to infections, and booster vaccination is frequently recommended, as for pneumococcus and influenza pathogens. Although limited data are available, patients with autoimmune disease and frequently with end-organ damage are likely to be at increased risk of severe COVID-19 disease and complications. COVID-19 vaccination is therefore preferable to non-vaccination and should be encouraged.

**Known immunodeficiency (primary or secondary) and immunosuppressive therapy**

There are several groups of patients, largely excluded from current phase III vaccine trials, with immunodeficiency, including patients with: (i) inborn errors of immunity; (ii) malignancies, especially haematological cancers with immunoparesis; and (iii) haematopoietic stem cell and solid organ transplant patients, who are all considered at increased risk for severe COVID-19 disease. The immunological response to COVID-19 vaccination is likely to be heterogeneous among these patients. HIV patients are another very large and important group of immunodeficiency patients in SA, but fortunately relevant trials have included stable HIV patients on antiretrovirals and with suppressed viral loads, so specific immunogenicity and vaccine efficacy data will soon be available to guide use in this large and important SA patient group. Lastly, patients on chronic immunosuppressive therapy are another at-risk group where vaccination will be off-label. Fortunately, however, safety of non-live vaccines is not likely to be an issue or a contraindication to use for any of these groups, and where possible it will be reasonable to consider off-label vaccination. Individual patients should contact their specialist if they are concerned, for a case-by-case risk assessment. All patients in these groups should be clearly counselled that the effectiveness of vaccination will be unknown and every effort to avoid infection should still be implemented, especially during surges.

**Additional safety precautions**

Places of vaccination should all be equipped to manage cases of anaphylaxis should they occur. Preparation includes the availability of emergency equipment, the latest anaphylaxis algorithm, and staff trained in the management of anaphylaxis. It is recommended that prior to the start of each vaccination day, the staff team should identify roles and responsibilities in the case of an emergency, including the appropriate evacuation of patients to intensive care settings. High-risk allergic patients should not be vaccinated by small mobile outreach vaccine teams, where availability of equipment and trained staff is limited. The majority of drug- and vaccine-induced anaphylaxis occurs within 30 minutes of dosing, including the recent cases related to the mRNA COVID-19 vaccines, with 71% of allergic reactions to the Pfizer BioNTech COVID-19 mRNA vaccine occurring within 15 minutes of vaccination. It is therefore recommended that allergic patients should be observed at the vaccine health centre for 30 rather than the routine 15 minutes after dosing.
Conclusions
Vaccination offers the opportunity for both individual and, with sufficient coverage, herd protection against SARS-CoV-2 infection and disease; if vaccination is safe and available, it should therefore be done. Vaccination should only be contraindicated in the very small group of patients with a prior anaphylactic reaction to either the first dose of COVID-19 vaccine or an ingredient in the vaccine formulation, e.g. PEG. However, given the emerging nature of efficacy data and the exclusion of certain subgroups of patients with immune-based disease, counselling of patients must make it clear regarding where vaccine effectiveness is unknown and may be reduced, and all other efforts to avoid infection must continue.

Declaration. None.

Acknowledgements. Editorial inputs from Elizabeth Phillips.

Author contributions. Sole author.

Funding. None.

Conflicts of interest. None.


Accepted 27 January 2021.